Diisopropylethylamine → HCID 66856359, compound

HRID 1970601Notes

Reaction equation

HRID 1970601 reaction equation
[CH:1]1([NH:5][C:6]([C@@H:8]2[CH2:12][CH2:11][CH2:10][N:9]2[C:13](=[O:34])[CH2:14][O:15][C:16]2[N:20]([C:21]3[CH:26]=[CH:25][CH:24]=[CH:23][CH:22]=3)[N:19]=[C:18]([C:27]([NH:29][CH2:30][C:31]([OH:33])=O)=[O:28])[CH:17]=2)=[O:7])[CH2:4][CH2:3][CH2:2]1.CCN(C(C)C)C(C)C.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[CH:68]1([O:72][C:73]([N:75]2[CH2:80][CH2:79][NH:78][CH2:77][CH2:76]2)=[O:74])[CH2:71][CH2:70][CH2:69]1>CN(C=O)C.ClCCl>[CH:68]1([O:72][C:73]([N:75]2[CH2:80][CH2:79][N:78]([C:31](=[O:33])[CH2:30][NH:29][C:27]([C:18]3[CH:17]=[C:16]([O:15][CH2:14][C:13]([N:9]4[CH2:10][CH2:11][CH2:12][C@H:8]4[C:6](=[O:7])[NH:5][CH:1]4[CH2:4][CH2:3][CH2:2]4)=[O:34])[N:20]([C:21]4[CH:22]=[CH:23][CH:24]=[CH:25][CH:26]=4)[N:19]=3)=[O:28])[CH2:77][CH2:76]2)=[O:74])[CH2:71][CH2:70][CH2:69]1

Participants

7

Reactant 4

HCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 668544701-CyclobutoxycarbonylpiperazineHCID 66855161HCID 66855161, compound

Product 1

HCID 66856359HCID 66856359, compound

Reagents, catalysts & solvents 2

HCID 6228DimethylformamideSolventHCID 6344DichloromethaneSolvent

Procedure

To a solution of 100 mg ({5-[2-((S)-2-Cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-acetic acid in 2 ml DMF were added 0.15 ml DIPEA, 81 mg HATU and 0.03 mg 1-cyclobutoxycarbonylpiperazine. After stirring for 1 h it was diluted with dichloromethane and extracted with aqueous LiCl (4% w/w), aqueous NaHCO3 and 0.1 M HCl. The crude product obtained after evaporation of the solvent was purified by preparative HPLC (C18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA) to give the title compound.

Workup

  1. extractionextracted with aqueous LiCl (4% w/w), aqueous NaHCO3 and 0.1 M HCl
  2. customThe crude product obtained
  3. customafter evaporation of the solvent
  4. customwas purified by preparative HPLC (
  5. washC18 reverse phase column, elution with a water/MeCN gradient with 0.1% TFA)

Sources & evidence

ORD record
ord-3b03e38f0cac4ad6b48b3e10014e252c
Source dataset
uspto-grants-2013_04
Patent number
US08426420B2

Reaction notes

Loading…